Prevacid Related Published Studies
Well-designed clinical trials related to Prevacid (Lansoprazole)
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. [2008.04]
Clinical response to 2 dosing regimens of lansoprazole in infants with gastroesophageal reflux. [2008.03]
Initial treatment with lansoprazole in young dyspeptic patients with negative urea breath test result: a randomized controlled trial with 12-month follow-up. [2007.07]
Acid control with esomeprazole and lansoprazole: a comparative dose-response study. [2007.02]
Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. [2006.10]
A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. [2006.07]
Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. [2006.07]
Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve. [2006.06]
Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. [2006.04.15]
Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages. [2006.04.01]
Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h. [2006.04.01]
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. [2006.02.01]
Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. [2006.02]
Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: A comparison between two different daily doses of lansoprazole. [2006.01.07]
Intestinal CYP3A4 is not involved in the enantioselective disposition of lansoprazole. [2006.01]
Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. [2006.01]
Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers. [2006]
Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. [2005.11]
Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. [2005.10.01]
Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. [2005.09]
A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. [2005.07.15]
Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. [2005.07.01]
Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry. [2005.07]
Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. [2005.07]
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine. [2005.06]
Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes. [2005.06]
Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. [2005.05]
Helicobacter pylori eradication using tetracycline and furazolidone versus amoxicillin and azithromycin in lansoprazole based triple therapy: an open randomized clinical trial. [2005.04]
Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes. [2005.03]
Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. [2005.02.15]
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. [2004.12]
Comparison of the pharmacokinetics of lansoprazole 15- and 30-mg sachets for suspension versus intact capsules. [2004.12]
Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. [2004.11]
Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. [2004.10.15]
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. [2004.10]
Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. [2004.09.15]
A novel option in proton pump inhibitor dosing: lansoprazole orally disintegrating tablet dispersed in water and administered via nasogastric tube. [2004.08.15]
Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection. [2004.07.31]
Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. [2004.07.01]
A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe. [2004.06.01]
Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. [2004.06.01]
The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial. [2004.05.15]
Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole. [2004.05.15]
Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease. [2004.02.15]
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. [2003.12]
Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. [2003.12]
Nutcracker oesophagus: a double-blind, placebo-controlled, cross-over study of the effects of lansoprazole. [2003.12]
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. [2003.10.15]
Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. [2003.09]
Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. [2003.04]
Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo. [2003.03.15]
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. [2003.02]
Review article: esomeprazole, 40 mg once daily, compared with lansoprazole, 30 mg once daily, in healing and symptom resolution of erosive oesophagitis. [2003.02]
Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. [2003.02]
Comparative pharmacokinetics and safety of lansoprazole oral capsules and orally disintegrating tablets in healthy subjects. [2003.02]
Influence of lansoprazole, famotidine, roxatidine and rebamipide administration on the urea breath test for the diagnosis of Helicobacter pylori infection. [2003.02]
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. [2003.01]
Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. [2003.01]
Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. [2003]
Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin after simultaneous and single administration. [2002.11]
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. [2002.11]
Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible Helicobacter pylori infection. [2002.10]
Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. [2002.10]
Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine. [2002.09]
Bioavailability of lansoprazole granules administered in juice or soft food compared with the intact capsule formulation. [2002.08]
Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol. [2002.07]
Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. [2002.06.27]
On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. [2002.06]
Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. [2002.06]
A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial. [2002.06]
Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. [2002.03]
Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test. [2002.03]
Acid suppression in healthy subjects following lansoprazole or pantoprazole. [2002.03]
Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. [2002.02]
Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. [2002.01.28]
Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection. [2002.01]
Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison. [2002.01]
Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. [2002]
Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. [2001.11]
Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. [2001.11]
Health-Related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine. [2001.11]
A comparison of simplified lansoprazole suspension administered nasogastrically and pantoprazole administered intravenously: effects on 24-h intragastric pH. [2001.11]
Ultrashort regimen of lansoprazole-amoxicillin-azithromycin for eradicating Helicobacter pylori. [2001.10.01]
A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers. [2001.10]
Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. [2001.09]
A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. [2001.09]
Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects. [2001.08.15]
Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. [2001.08]
Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. [2001.07]
Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study. [2001.06]
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. [2001.05]
Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg. [2001.05]
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. [2001.04]
Pantoprazole versus lansoprazole in French patients with reflux esophagitis. [2001.03]
Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model. [2001.03]
Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast and Lanzor) in healthy volunteers. [2001.03]
Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. [2001.01]
Duration of effect of lansoprazole on gastric pH and acid secretion in normal male volunteers. [2001.01]
A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. [2001]
Effects of lansoprazole on human gastric lipase secretion and intragastric lipolysis in healthy human volunteers. [2001]
Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-centre study. [2000.12]
|
